[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"psa-psoriatic-arthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:psa-psoriatic-arthritis":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100617164",false,"NCT07315061","A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis","Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis","D2570-204","Inclusion Criteria:\n\n1. Subjects voluntarily take part in the study after being fully informed, sign a written informed consent form (ICF), and agree to follow procedures specified in the study protocol;\n2. Males and females, 18 to 70 years of age, inclusive at the time of signing of ICF;\n3. Have had an psoriatic arthritis of ≥ 3 months in duration prior to signing of ICF;\n4. Have had active arthritis, characterized by at least ≥3 tender joints (68 joint tenderness counts) and ≥3 swollen joints (66 joint swelling counts).\n\nExclusion Criteria:\n\n1. History of infection as defined in the protocol;\n2. Any of the medical diseases or disorders listed in the protocol;\n3. Significant, uncontrolled or unstable disease in any organ.","ALL","18 Years","70 Years",{"count":20,"type":21},222,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with active psoriatic arthritis. A total of 222 subjects are planned to be included.",[27],"PsA (Psoriatic Arthritis)",[27],"RECRUITING","2026-04-21",{"date":32,"type":33},"2026-04-22","ACTUAL",{"date":35,"type":33},"2026-01-16",{"date":37,"type":21},"2028-08-06",{"name":39,"class":40},"InventisBio Co., Ltd","INDUSTRY",""]